Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D All News, Vivo News Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&Dartrix2020-07-09T11:12:39-07:00July 9th, 2020|Read More
Legend Biotech Raises $150.5 Million in Series A Preferred Financing To Advance its Oncology Pipeline and Platform Legend Biotech Raises $150.5 Million in Series A Preferred Financing To Advance its Oncology Pipeline and Platform All News, Portfolio News, Vivo News Legend Biotech Raises $150.5 Million in Series A Preferred Financing To Advance its Oncology Pipeline and Platformartrix2020-04-21T13:06:00-07:00April 21st, 2020|Read More
Vivo Capital Closes $1.43 Billion Fund IX to Invest in Healthcare and Life Science Companies Vivo Capital Closes $1.43 Billion Fund IX to Invest in Healthcare and Life Science Companies All News, Vivo News Vivo Capital Closes $1.43 Billion Fund IX to Invest in Healthcare and Life Science Companiesartrix2019-10-30T13:46:20-07:00October 30th, 2019|Read More
12 VCs who matter in biotech, but you never read about 12 VCs who matter in biotech, but you never read about All News, Vivo News 12 VCs who matter in biotech, but you never read aboutartrix2019-11-05T22:24:30-08:00October 9th, 2019|Read More
Swift Health Systems Raises $45 Million in Series C Funding Swift Health Systems Raises $45 Million in Series C Funding All News, Vivo News Swift Health Systems Raises $45 Million in Series C Fundingartrix2020-01-22T00:27:56-08:00October 8th, 2019|Read More
Vivo Capital to Sponsor New Frontier Corporation’s Acquisition of United Family Healthcare Vivo Capital to Sponsor New Frontier Corporation’s Acquisition of United Family Healthcare All News, Portfolio News, Vivo News Vivo Capital to Sponsor New Frontier Corporation’s Acquisition of United Family Healthcareartrix2020-01-22T00:29:14-08:00July 30th, 2019|Read More
Impel NeuroPharma Closes $67.5 Million Series D Financing Impel NeuroPharma Closes $67.5 Million Series D Financing All News, Portfolio News, Vivo News Impel NeuroPharma Closes $67.5 Million Series D Financingartrix2019-10-19T05:34:48-07:00December 6th, 2018|Read More
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China All News, Portfolio News, Vivo News Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in Chinaartrix2019-10-19T05:35:03-07:00November 8th, 2018|Read More
Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer All News, Portfolio News, Vivo News Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancerartrix2019-10-19T05:35:16-07:00October 30th, 2018|Read More
Vivo Capital Closes Oversubscribed $635 Million Fund to Invest in Public Healthcare Equities Vivo Capital Closes Oversubscribed $635 Million Fund to Invest in Public Healthcare Equities All News, Vivo News Vivo Capital Closes Oversubscribed $635 Million Fund to Invest in Public Healthcare Equitiesartrix2019-10-19T05:31:53-07:00September 11th, 2018|Read More
Sinovac Raises $86.73 Million Through Private Placement Transaction Sinovac Raises $86.73 Million Through Private Placement Transaction All News, Portfolio News, Vivo News Sinovac Raises $86.73 Million Through Private Placement Transactionartrix2019-10-19T05:35:28-07:00July 3rd, 2018|Read More
Vivo Capital’s Evolving “Bridge Strategy” Helps Nanjing King-friend Go Public Vivo Capital’s Evolving “Bridge Strategy” Helps Nanjing King-friend Go Public All News, Vivo News Vivo Capital’s Evolving “Bridge Strategy” Helps Nanjing King-friend Go Publicartrix2019-10-19T05:32:24-07:00August 1st, 2017|Read More
Vivo Capital Closes First Healthcare Venture Capital Focused Fund at Over $100 Million Vivo Capital Closes First Healthcare Venture Capital Focused Fund at Over $100 Million All News, Vivo News Vivo Capital Closes First Healthcare Venture Capital Focused Fund at Over $100 Millionartrix2019-10-19T05:32:32-07:00June 13th, 2016|Read More
Vivo Capital Closes Oversubscribed $750 Million 8th Fund to Invest in Healthcare in the U.S. and Greater China Vivo Capital Closes Oversubscribed $750 Million 8th Fund to Invest in Healthcare in the U.S. and Greater China All News, Vivo News Vivo Capital Closes Oversubscribed $750 Million 8th Fund to Invest in Healthcare in the U.S. and Greater Chinaartrix2019-10-19T05:32:39-07:00March 17th, 2015|Read More
Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China All News, Vivo News Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater Chinaartrix2019-10-19T05:32:47-07:00January 3rd, 2012|Read More
